Case

Jeroen Kortekaas

Jeroen Kortekaas has devoted his career to vaccine development. He received his PhD from the Utrecht University, after completing his thesis on the “Vaccine potential of iron-regulated outer membrane receptors of Neisseria meningitidis”.

Epidemiology and pathogenesis of Rift Valley fever virus

These studies were performed at the Department of Microbiology, under the supervision of Prof. Jan Tommassen and Dr. Martine Bos. He then moved to CVI where he developed a novel live-attenuated Classical swine fever vaccine that allows the Differentiation between Infected and Vaccinated Animals (DIVA). He subsequently joined forces with Prof. Rob Moormann to establish a new research group focused on vaccine development against Rift Valley fever virus (RVFV). Between 2007 and 2009, biosafety level-3 (enhanced) containment facilities for both animal and laboratory experimentation were established, as well as animal models and laboratory protocols. From 2009 until today, several experimental RVF vaccines were developed, of which two are currently being developed further by pharmaceutical companies. Apart from continuing research on RVFV, his team will expand expertise on Phlebovirus, Nairovirus and Orthobunyavirus vaccine development in the years to come. After the retirement of Prof. Moormann, Jeroen will be head of the bunyavirus research group.